MaxCyte, Inc. - Common Stock (MXCT)
Frequently Asked Questions About MaxCyte, Inc. - Common Stock (MXCT)
How does MaxCyte contribute to the scientific community?
MaxCyte contributes to the scientific community by providing access to its technologies for academic research, publishing scientific findings, and participating in conferences to promote knowledge exchange and collaboration in the field of cell biology and therapeutics.
How does MaxCyte ensure quality control?
MaxCyte ensures quality control through strict compliance with regulatory standards and guidelines, implementing rigorous testing protocols for its products to guarantee their safety, efficacy, and performance for therapeutic applications.
How does MaxCyte support cell therapy development?
MaxCyte supports cell therapy development by providing scalable and efficient cell engineering solutions that significantly reduce time and resource demands in generating modified cell lines, ultimately streamlining the research and production processes.
How has MaxCyte performed financially?
MaxCyte has experienced considerable growth in revenue due to the increasing demand for cell engineering technologies amidst the expanding market for cell and gene therapies, reflecting positively on its financial performance since its IPO.
Is MaxCyte a publicly traded company?
Yes, MaxCyte is publicly traded on the Nasdaq stock exchange under the ticker symbol MXCT. The company went public through an initial public offering (IPO) to raise capital for its growth initiatives and technology development.
What are MaxCyte's primary products?
MaxCyte's primary products include its CLX and ATX electroporation instruments, which are used for high-performance cell transfection, and proprietary transfection reagents designed to deliver nucleic acids efficiently into various cell types.
What collaborations has MaxCyte established?
MaxCyte has established numerous collaborations and partnerships with leading pharmaceutical and biotechnology companies, enabling them to leverage MaxCyte’s technologies for enhancing their own product development pipelines in cell and gene therapy.
What does MaxCyte, Inc. do?
MaxCyte, Inc. is a biotechnology company that specializes in cell-based therapies and drug discovery. It provides high-performance cell engineering technology that allows researchers and developers to optimize cells for therapeutic purposes, enhancing the development of innovative cell therapies and biologics.
What future plans does MaxCyte have?
MaxCyte plans to expand its research capabilities, enhance its product offerings, and cultivate deeper partnerships in the biopharmaceutical sector, aiming to solidify its position as a leader in cell engineering technologies as the industry evolves.
What is a notable achievement of MaxCyte?
A notable achievement of MaxCyte includes receiving regulatory approvals for its technology in various therapeutic applications, showcasing its efficacy and addressing critical challenges in the cell transfection space.
What is the mission of MaxCyte?
MaxCyte's mission is to empower researchers and developers in the biopharmaceutical space by providing advanced cell engineering technologies that enhance the development and delivery of life-saving therapies for patients worldwide.
What is the role of R&D at MaxCyte?
Research and development (R&D) at MaxCyte plays a crucial role in advancing the company's technologies and expanding its product portfolio, enabling continuous improvement in cell engineering methods and fostering innovation in therapeutic solutions.
What is the vision of MaxCyte?
MaxCyte’s vision is to be a leading global provider of cell engineering technologies, driving innovations that will vastly improve treatment outcomes for patients with serious diseases through the development of one-time curative therapies.
What technologies does MaxCyte offer?
MaxCyte offers a range of technologies including the Flow Electroporation technology, which enables the rapid, efficient, and scalable transfection of cells to create genetically modified cell lines, supporting various applications in research and development.
What types of markets does MaxCyte serve?
MaxCyte serves a diverse range of markets, including biopharmaceutical companies, academic institutions, and research organizations engaged in developing cell therapies, gene therapies, and protein production.
When was MaxCyte founded?
MaxCyte was founded in 1998 and has since established itself as a leader in cell engineering and platform technologies aimed at improving cell therapy processes.
Where is MaxCyte located?
MaxCyte is headquartered in Rockville, Maryland, USA, strategically positioned near various biotechnology hubs and institutions, facilitating collaborations and partnerships in the industry.
Who are MaxCyte's main competitors?
MaxCyte competes with other biotechnology companies offering similar cell transfection technologies and services, including companies focused on electroporation, viral transduction, and other gene delivery methods, aiming to improve cell modification efficiencies.
What is the current price of MaxCyte, Inc. - Common Stock?
The current price of MaxCyte, Inc. - Common Stock is 2.760
When was MaxCyte, Inc. - Common Stock last traded?
The last trade of MaxCyte, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025